Patents by Inventor Christopher Thanos
Christopher Thanos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250025210Abstract: Macroencapsulation implantation devices and containers for storing a macroencapsulation device disposed within a receptacle of a macroencapsulation implantation device as well as related methods are described. In some embodiments, a macroencapsulation implantation device may include a handle that is configured to be selectively engaged with a receptacle including a recess in which a macroencapsulation device may be disposed. In some embodiments, a container may be configured to maintain a receptacle of a macroencapsulation implantation device, and a macroencapsulation device disposed therein, in a desired pose within an internal volume of the container.Type: ApplicationFiled: July 19, 2024Publication date: January 23, 2025Applicant: Vertex Pharmaceuticals IncorporatedInventors: Megan Billings, John Mills, John Fraser Mills, Noah Nguyen, Christopher Thanos
-
Patent number: 12194138Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.Type: GrantFiled: May 4, 2022Date of Patent: January 14, 2025Assignee: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, Yang Qiu
-
Publication number: 20240425817Abstract: Provided herein are, inter alia, compositions and methods for improved production of SC-? cells in vitro. For example, provided are novel formulations and differentiation methods that result in higher cell yields and recoveries, increased numbers and relative percentages of SC-? cells, enhanced stability and shelf-life of SC-? cells, SC-islet clusters with advantageous characteristics such as reduced size and increased uniformity, improved function of the SC-? cells in vitro, and improved viability, function, and reduced immunogenicity after transplantation. The disclosed compositions and methods can be employed in the manufacture of SC-islets for human therapeutic use.Type: ApplicationFiled: December 28, 2021Publication date: December 26, 2024Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Bryce CAREY, Aleksander SZYMANIAK, Christopher THANOS
-
Publication number: 20240382532Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.Type: ApplicationFiled: April 26, 2024Publication date: November 21, 2024Applicant: Vertex Pharmaceuticals IncorporatedInventors: George Harb, Chunhui Xie, Bryce W. Carey, Aleksander Szymaniak, Christopher Thanos, Evrett Thompson, Rebecca Chinn, Suyash Raj
-
Publication number: 20240352392Abstract: Macroencapsulation devices and related methods of manufacture are described where bonded membranes of a device may be mounted to an associated frame in an arrangement to provide stress relief between the frame and a seal perimeter of the bonded membranes. The seal perimeter may be arranged radially inward from an outer perimeter of the membranes such that when the membranes are mounted to a corresponding perimeter frame, the seal perimeter is spaced radially inwards from the frame with a unbonded portion of the one or more membranes disposed between the frame and seal perimeter.Type: ApplicationFiled: August 16, 2022Publication date: October 24, 2024Applicant: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, John Mills, Matthew Watson, Rahul R. Rajendran, Noah Nguyen
-
Publication number: 20240342077Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of chemicals to increase the ratio of surface area to volume.Type: ApplicationFiled: September 21, 2023Publication date: October 17, 2024Applicant: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
-
Patent number: 11992506Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.Type: GrantFiled: November 1, 2022Date of Patent: May 28, 2024Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: George Harb, Chunhui Xie, Bryce W. Carey, Aleksander Szymaniak, Christopher Thanos, Evrett Thompson, Rebecca Chinn, Suyash Raj
-
Publication number: 20240148642Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.Type: ApplicationFiled: January 18, 2024Publication date: May 9, 2024Applicant: Vertex Pharmaceuticals IncorporatedInventors: CHRISTOPHER THANOS, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
-
Patent number: 11951206Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.Type: GrantFiled: September 29, 2018Date of Patent: April 9, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
-
Publication number: 20240033216Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of chemicals to increase the ratio of surface area to volume.Type: ApplicationFiled: September 21, 2023Publication date: February 1, 2024Applicant: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
-
Publication number: 20230390400Abstract: A method of manufacturing a macroencapsulation device includes aligning one or more membranes of the device with a frame of the device, such that a portion of the one or more membranes overlap a portion of the frame. The method also includes deforming the one or more membranes and thermoplastically deforming the frame to form mechanically interlocked regions of the membrane and the frame.Type: ApplicationFiled: June 6, 2023Publication date: December 7, 2023Applicant: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, Megan Billings, Matthew Watson
-
Publication number: 20230332107Abstract: Disclosed herein are compositions, kits, and methods related to cell therapy for a disease characterized by high blood glucose levels over a long period of time, such as diabetes. In some aspects, the methods provided herein relate to administration of non-native pancreatic cells to subject with a disease characterized by high blood glucose levels over a long period of time, such as diabetes. In some aspects, the disclosure provides pharmaceutical compositions including non-native cells.Type: ApplicationFiled: January 31, 2023Publication date: October 19, 2023Inventors: Felicia PAGLIUCA, George HARB, Jason GAGLIA, Andrea VERGANI, Christopher THANOS
-
Publication number: 20230242895Abstract: Provided are nucleic acid molecules, including vectors and plasmids, encoding modified u-PA polypeptides and fusion proteins containing the modified u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The nucleic acids and encoded modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.Type: ApplicationFiled: February 10, 2023Publication date: August 3, 2023Inventors: Edwin L. MADISON, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
-
Publication number: 20230218676Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.Type: ApplicationFiled: November 1, 2022Publication date: July 13, 2023Applicant: Vertex Pharmaceuticals IncorporatedInventors: George Harb, Chunhui Xie, Bryce W. Carey, Aleksander Szymaniak, Christopher Thanos, Evrett Thompson, Rebecca Chinn, Suyash Raj
-
Patent number: 11613744Abstract: Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.Type: GrantFiled: January 3, 2020Date of Patent: March 28, 2023Assignee: Vertex Pharmaceuticals IncorporatedInventors: Edwin L. Madison, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
-
Publication number: 20220331234Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.Type: ApplicationFiled: May 4, 2022Publication date: October 20, 2022Applicant: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, Yang Qiu
-
Patent number: 11471398Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.Type: GrantFiled: March 6, 2019Date of Patent: October 18, 2022Assignee: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, Yang Qui
-
Publication number: 20220175511Abstract: The present disclosure relates to macroencapsulation devices and related methods of manufacture where the membranes of a device may be mounted to an associated frame in a relaxed, or slack, configuration prior to filling with a desired material.Type: ApplicationFiled: April 2, 2020Publication date: June 9, 2022Applicant: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, Danya M. Lavin, John Mills, Megan Billings
-
Publication number: 20220143374Abstract: Macroencapsulation devices and their methods of use are disclosed. In one embodiment, a macroencapsulation device may include a first outer membrane, a second outer membrane, and at least one semipermeable membrane disposed there between to form at least a primary compartment configured to house a first population of cells and a secondary compartment in fluid communication with the primary compartment through the first semipermeable membrane. In some embodiments, the flow of material into and out of the compartments of the macroencapsulation device and/or the application of an appropriate pressure differential between the compartments may be used to control the flow of filtrates, ancillary agents, and other materials between the compartments of the device when positioned in vivo.Type: ApplicationFiled: April 2, 2020Publication date: May 12, 2022Applicant: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, John Mills, Megan Billings
-
Patent number: 11203749Abstract: Nucleic acids encoding modified factor VII polypeptides, vectors and cells containing the nucleic acids, uses of the nucleic acids, methods of making the encoded polypeptides, and methods of treatment are provided. The encoded modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among the encoded modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities.Type: GrantFiled: November 2, 2018Date of Patent: December 21, 2021Assignee: CATALYST BIOSCIENCES, INC.Inventors: Edwin L. Madison, Christopher Thanos